Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

HOWL Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Werewolf Therapeutics, Inc.NASDAQ: HOWL

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents falls 71.7% from a year ago

Cash & equivalents stood at $21.99M at the end of Q2 FY2026, down 71.7% from a year earlier and down 52.7% from the prior quarter. Over 3 fiscal years it compounded at -23.5% a year.

Context

  • Cash & equivalents amounted to 91.0% of total assets at the end of Q2 FY2026, up 7.2 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -71.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$21.99M-52.7% QoQ
Last fiscal yearDec 2025
$57.95M-47.8% YoY
Year agoJun 2025
$77.6M-71.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.7%——
1 year-47.8%——
3-year CAGR-23.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
57.95M USD
Year-over-year change
-47.8%
4-year CAGR
-22.1%

Cash & Equivalents vs competitors

How HOWL compares with its peers on the latest reported figures

  • HOWL's Jun 2026 cash & equivalents of $21.99M is the 4th highest of the 8 companies compared; the peer median is $21.36M.
  • Its year-over-year change of -71.7% is the lowest of 8, against a peer median of +24.7%.
  • Cash & equivalents amounts to 91.0% of total assets for HOWL, versus a peer median of 56.4%.
HOWL Competitors Peer median
Cash & Equivalents for HOWL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OSTXOS Therapies IncorporatedMar 2026$917.55M +30783.5%+1063.1%12570.5%
SPRBSpruce Biosciences, Inc.Mar 2026$54.08M +111.1%+25.9%96.3%
ACETAdicet Bio, Inc.Mar 2026$36.25M +28.8%-46.7%21.4%
HOWLWerewolf Therapeutics, Inc.Jun 2026$21.99M -71.7%-23.5%91.0%
INMBINmune Bio, Inc.Mar 2026$21.36M +10.5%-22.0%82.7%
CUECue Biopharma, Inc.Mar 2026$16.38M +24.7%-19.3%53.0%
OTLKOutlook Therapeutics, Inc.Mar 2026$7.75M +2.5%-22.5%35.4%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$6.71M +21.0%-27.0%56.4%
Peer median (excluding HOWL) $21.36M+24.7%-22.0%56.4%

Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents157.53M129.32M134.34M111M57.95M
Short-term Investments00000
Net Receivables06.93M1.35M00
Inventory00000
Other Current Assets100K3.96M2.68M2.07M635K
Total Current Assets161.07M140.2M138.37M113.07M58.59M
Property, Plant & Equipment (Net)16.33M17.45M14.85M12.32M9.9M
Goodwill00000
Intangible Assets00000
Long-term Investments01.21M21.02M1.22M901K
Tax Assets00000
Other Non-current Assets1.86M1.38M594K320K5K
Total Non-current Assets18.18M20.05M36.46M13.86M10.81M
Total Assets179.25M160.25M174.83M126.93M69.4M
Account Payables2.04M1.22M1.34M3.04M754K
Short-term Debt006.67M01.75M
Tax Payables00000
Deferred Revenue06.53M907K00
Other Current Liabilities163K11.02M3.63M3.62M33.64M
Total Current Liabilities11.87M23.99M19.38M15.18M36.15M
Long-term Debt0032.66M26.1M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities01.32M433K2.83M759K
Total Non-current Liabilities14.59M13.92M44.08M38.36M8.44M
Total Liabilities26.46M37.91M63.46M53.54M44.59M
Common Stock2K3K4K5K5K
Retained Earnings(252.9M)(306.71M)(344.07M)(414.59M)(475.41M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity152.79M122.34M111.37M73.39M24.81M
Total Debt15.66M14.68M51.92M37.09M9.44M
Net Debt(141.87M)(114.63M)(82.42M)(73.91M)(48.52M)

Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.